Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MGLL | Q99685 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 4/20 | 0.46 |
| ▸ | PHGDH | O43175 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27521010 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL29009228 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL27649469 | 0.83 | PKM (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL31364230 | 0.82 | ALDH1A1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL9872134 | 0.82 | ALDH1A1 (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL27961635 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL27629377 | 0.80 | ALDH1A1 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL27992329 | 0.79 | ALDH1A1 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL27992542 | 0.78 | ALDH1A1 (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL | |
| SCHEMBL27629390 | 0.78 | MGLL (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11575156-B2 | Diselenoester electrolyte additives for fast charging lithium ion batteries | StoreDot Ltd. (IL) | 2023-02-07 | — | — | US | disclosed |
| US-20210242497-A1 | DISELENOESTER ELECTROLYTE ADDITIVES FOR FAST CHARGING LITHIUM ION BATTERIES | StoreDot Ltd. (IL) | 2021-08-05 | — | — | US | disclosed |
| US-20210242500-A1 | ELECTROLYTES FOR FAST CHARGING LITHIUM ION BATTERIES HAVING FOUR-CARBON CHAIN ESTERS AS LINEAR COMPONENTS | StoreDot Ltd. (IL) | 2021-08-05 | — | — | US | disclosed |
| US-20210234197-A1 | ELECTROLYTE ADDITIVES FOR FAST CHARGING LITHIUM ION BATTERIES | StoreDot Ltd. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-20190356013-A1 | ELECTROLYTE ADDITIVES IN LITHIUM-ION BATTERIES | StoreDot Ltd. (IL) | 2019-11-21 | — | — | US | disclosed |
| EP-3235815-A1 | AGENTS AGAINST PARASITIC HELMINTHS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-05 | — | — | US | disclosed |
| WO-2007012630-A1 | CONDUCTIVE OR SEMI-CONDUCTIVE MATERIAL MODIFIED BY ELECTROCHEMICAL GRAFTING OF POLYMER FILMS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | CCKAR, CCKBR, GRPR | SMN1; SMN2 1376/4885NPC1 3648/4885RAB9A 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.